RCTs deliver the most reliable evidence to guide how we treat our patients but they are badly designed, inaccurately reported and misunderstood. We can do better.
Why science by press release is bad, despite optimism about the findings of the Recovery trial and the role of dexamethasone in the management of COVID-19.
A fascinating talk by Jack Iwashyna (@iwashyna) on the 'heterogeneity of treatment' effect, what this means for the conduct of randomised control trials and how we should interpret them.